Status:
COMPLETED
Belinostat in Treating Patients With Myelodysplastic Syndromes
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial is studying how well belinostat works in treating patients with myelodysplastic syndromes. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for...
Detailed Description
OBJECTIVES: I. Establish the efficacy and safety of PXD101 (belinostat) in patients with myelodysplastic syndromes that progressed after or is ineligible for azacitidine treatment. II. Assess the bi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed myelodysplastic syndromes (MDS)
- De novo or secondary MDS
- Patients with \< 5 % bone marrow blasts must meet ≥ 1 of the following criteria:
- Symptomatic anemia with either hemoglobin \< 10.0 g/dL or required RBC transfusions within the past 3 months
- Thrombocytopenia with ≥ 2 platelet counts \< 50,000/mm³ or significant hemorrhage requiring platelet transfusions
- Neutropenia with ≥ 2 absolute neutrophil counts \< 1,000/mm³
- No acute myeloid leukemia (≥ 20% bone marrow blasts)
- ECOG performance status 0-2
- Life expectancy \> 12 weeks
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST ≤ 2 times ULN
- Creatinine ≤ 2.0 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD101
- No HIV positivity
- QTc interval ≤ 500 msec
- No long QT syndrome
- No significant cardiovascular disease, including any of the following:
- Unstable angina pectoris
- Uncontrolled hypertension
- Congestive heart failure related to primary cardiac disease
- Condition requiring anti-arrhythmic therapy
- Ischemic or severe valvular heart disease
- Myocardial infarction within the past 6 months
- No other uncontrolled serious medical condition (e.g., cardiac arrhythmias or diabetes)
- Recovered from prior therapy
- No more than 2 prior therapies for MDS
- Prior hematopoietic growth factors, androgens, and other supportive care agents allowed and are not considered in the prior therapy total
- No prior allogeneic stem cell transplantation
- More than 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- No prior histone deacetylase (HDAC) inhibitors for treatment of MDS
- More than 2 weeks since prior valproic acid or other HDAC inhibitors
- No other concurrent investigational agents
- No concurrent medication that may cause torsades depointes, including any of the following:
- Disopyramide
- Dofetilide
- Ibutilide
- Procainamide
- Quinidine
- Sotalol
- Bepridil
- Methadone
- Amiodarone hydrochloride
- Arsenic trioxide
- Cisapride
- Calcium-channel blockers (e.g., lidoflazine)
- Anti-infective agents (i.e., clarithromycin, erythromycin, halofantrine, pentamidine, or sparfloxacin)
- Domperidone or droperidol
- Antipsychotic agents (i.e., chlorpromazine, haloperidol, mesoridazine, thioridazine, or pimozide)
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00357162
Start Date
May 1 2006
End Date
December 1 2010
Last Update
May 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905